Cargando…
Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma
AIM: To evaluate the safety and efficacy of the administration of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the short term to the same patients in Barcelona Clinical Liver Cancer (BCLC) stages 0–B1. METHODS: From April 2014 to June 2019, we retrospectively reviewed B...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785216/ https://www.ncbi.nlm.nih.gov/pubmed/33400718 http://dx.doi.org/10.1371/journal.pone.0245076 |
_version_ | 1783632395843403776 |
---|---|
author | Wang, Feiqian Numata, Kazushi Takeda, Atsuya Ogushi, Katsuaki Fukuda, Hiroyuki Hara, Koji Chuma, Makoto Eriguchi, Takahisa Tsurugai, Yuichirou Maeda, Shin |
author_facet | Wang, Feiqian Numata, Kazushi Takeda, Atsuya Ogushi, Katsuaki Fukuda, Hiroyuki Hara, Koji Chuma, Makoto Eriguchi, Takahisa Tsurugai, Yuichirou Maeda, Shin |
author_sort | Wang, Feiqian |
collection | PubMed |
description | AIM: To evaluate the safety and efficacy of the administration of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the short term to the same patients in Barcelona Clinical Liver Cancer (BCLC) stages 0–B1. METHODS: From April 2014 to June 2019, we retrospectively reviewed BCLC stage 0–B1 patients with fresh hepatocellular carcinoma (HCC) lesions that were repeatedly treated by RFA (control group, n = 72), and by RFA and subsequent SBRT (case group, n = 26). Propensity score matching (PSM) was performed to reduce the selection bias between two groups. Recurrence, survival, Child–Pugh scores and short-term side effects (fever, bleeding, skin change, abdominal pain and fatigue) were recorded and analyzed. RESULTS: After PSM, 21 patients remained in each group. Seventeen and 20 patients in the case and control groups experienced recurrence. For these patients, the median times to progression and follow-up were 10.7 and 35.8 months, respectively. After PSM, the 1-year progression-free survival rate in case and control groups were 66.7% and 52.4%, respectively (P = 0.313). The inter-group overall survival (OS) was comparable (3 and 5-year OS rates in case groups were 87.3% and 74.8%, while rates in control groups were 73.7% and 46.3%, respectively; P = 0.090). The short-term side effects were mild, and the incidence showed no inter-group difference. The 1-year rates of the Child–Pugh score deterioration of ≥2 in case and control groups were 23.8% and 33.3% (P > 0.05), respectively. CONCLUSION: The short-term administration of RFA and SBRT to the same BCLC stage 0–B1 patients may be feasible and effective because of their good prognosis and safety. |
format | Online Article Text |
id | pubmed-7785216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-77852162021-01-13 Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma Wang, Feiqian Numata, Kazushi Takeda, Atsuya Ogushi, Katsuaki Fukuda, Hiroyuki Hara, Koji Chuma, Makoto Eriguchi, Takahisa Tsurugai, Yuichirou Maeda, Shin PLoS One Research Article AIM: To evaluate the safety and efficacy of the administration of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the short term to the same patients in Barcelona Clinical Liver Cancer (BCLC) stages 0–B1. METHODS: From April 2014 to June 2019, we retrospectively reviewed BCLC stage 0–B1 patients with fresh hepatocellular carcinoma (HCC) lesions that were repeatedly treated by RFA (control group, n = 72), and by RFA and subsequent SBRT (case group, n = 26). Propensity score matching (PSM) was performed to reduce the selection bias between two groups. Recurrence, survival, Child–Pugh scores and short-term side effects (fever, bleeding, skin change, abdominal pain and fatigue) were recorded and analyzed. RESULTS: After PSM, 21 patients remained in each group. Seventeen and 20 patients in the case and control groups experienced recurrence. For these patients, the median times to progression and follow-up were 10.7 and 35.8 months, respectively. After PSM, the 1-year progression-free survival rate in case and control groups were 66.7% and 52.4%, respectively (P = 0.313). The inter-group overall survival (OS) was comparable (3 and 5-year OS rates in case groups were 87.3% and 74.8%, while rates in control groups were 73.7% and 46.3%, respectively; P = 0.090). The short-term side effects were mild, and the incidence showed no inter-group difference. The 1-year rates of the Child–Pugh score deterioration of ≥2 in case and control groups were 23.8% and 33.3% (P > 0.05), respectively. CONCLUSION: The short-term administration of RFA and SBRT to the same BCLC stage 0–B1 patients may be feasible and effective because of their good prognosis and safety. Public Library of Science 2021-01-05 /pmc/articles/PMC7785216/ /pubmed/33400718 http://dx.doi.org/10.1371/journal.pone.0245076 Text en © 2021 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wang, Feiqian Numata, Kazushi Takeda, Atsuya Ogushi, Katsuaki Fukuda, Hiroyuki Hara, Koji Chuma, Makoto Eriguchi, Takahisa Tsurugai, Yuichirou Maeda, Shin Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title | Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title_full | Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title_fullStr | Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title_full_unstemmed | Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title_short | Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma |
title_sort | safety and efficacy study: short-term application of radiofrequency ablation and stereotactic body radiotherapy for barcelona clinical liver cancer stage 0–b1 hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785216/ https://www.ncbi.nlm.nih.gov/pubmed/33400718 http://dx.doi.org/10.1371/journal.pone.0245076 |
work_keys_str_mv | AT wangfeiqian safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT numatakazushi safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT takedaatsuya safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT ogushikatsuaki safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT fukudahiroyuki safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT harakoji safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT chumamakoto safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT eriguchitakahisa safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT tsurugaiyuichirou safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma AT maedashin safetyandefficacystudyshorttermapplicationofradiofrequencyablationandstereotacticbodyradiotherapyforbarcelonaclinicallivercancerstage0b1hepatocellularcarcinoma |